Comments*

 
  • Targeting Metals in Alzheimer's and Other Neurodegenerative Diseases

    Targeting Metals in Alzheimer's and Other Neurodegenerative Diseases

    Organizers: Rudolph Tanzi (Massachusetts General Hospital and Harvard Medical School), George Zavoico (MLV), and Jennifer Henry (The New York Academy of Sciences)
    Speakers: Robert A. Cherny (The Florey Institute of Neuroscience and Mental Health, Australia), Steven M. Hersch (Massachusetts General Hospital and Harvard Medical School), Rudolph Tanzi (Massachusetts General Hospital and Harvard Medical School), and Daniel Tardiff (Whitehead Institute for Biomedical Research)
    Presented by the Brain Dysfunction Discussion Group
    Reported by Jennifer Cable | Posted January 17, 2013

    Overview

    As life expectancy increases, the prevalence of age-related diseases will also increase. Efforts to develop therapies for age-related neurodegenerative diseases have yet to succeed in impacting disease pathogenesis; current treatments target only the symptoms, not the causes. To develop disease-modifying agents, some researchers aim to identify common features of neurodegenerative diseases that might provide clues to potential drug targets. On November 29, 2012, researchers investigating Alzheimer's, Parkinson's, and Huntington's diseases met at the New York Academy of Sciences to discuss one such feature—the effect of metals in neurodegenerative diseases—and to highlight clinical achievements using metal-binding compounds to influence disease progression. The symposium, Targeting Metals in Alzheimer's and Other Neurodegenerative Diseases, was presented by the Academy's Brain Dysfunction Discussion Group.

    Use the tabs above to find a meeting report and multimedia from this event.

    Presentations available from:
    Robert A. Cherny, PhD (The Florey Institute of Neuroscience and Mental Health, Australia)
    Steven M. Hersch, MD, PhD (Massachusetts General Hospital; Harvard Medical School)
    Rudolph Tanzi, PhD (Massachusetts General Hospital; Harvard Medical School)
    Daniel Tardiff, PhD (Whitehead Institute for Biomedical Research)
    Panel moderator: George Zavoico, PhD (MLV)


    Webinar & eBriefing Sponsor

    • Prana Biotechnology

    The Brain Dysfunction Discussion Group is proudly supported by


    • Acorda Therapeutics

    Mission Partner support for the Frontiers of Science program provided by Pfizer

    EmailPrint